Life Sciences Commercial, Sales & Marketing Services

What Is Driving This Change?

A New Experience Landscape

Actions to Modernize

Blogs

Case Studies

IDC MarketScape Leader

Life Science Sales & Marketing IT Outsourcing Services.

LEARN MORE

Changing relationships with customers

The life sciences industry is realizing unprecedented success in bringing New Science to market, with annual launches and approvals of new medicines at all-time highs. Yet, the marketplace within which we are launching these medicines has changed significantly – from a disrupted customer model accelerated by COVID-19, to slowing pricing and margin growth due to economic constraints, the continuously evolving role of patients and the structure of healthcare systems, and the ongoing possibilities of policy and regulatory forces constantly being explored.

Given this environment, how should biopharma’s realizing the optimal economic success of New Science?

It will require a more modernized commercial model – one that is fit for today and the future.

THE “NEW” RULES OF ENGAGEMENT [2021 HCP SURVEY]

720 HCPs on the interactions they want from pharma.

What is driving this change?

Pharma faces the need to modernize the commercial model based on these four pressures:

Customer engagement dynamic

COVID-19 has changed the ways customers learn about treatments and the support they need from life science companies.

Regulatory and policy reform

Mounting public pressures to reform drug pricing and are posing greater transparency in the value chain risk to access and reimbursement.

Private sector pressures

Private pressures such as competitive entrants are propelling the decline of net price.

Consumerism of patient care

New customer expectations across industries, the rise in digital therapeutics and non-traditional entrants in healthcare have created new demands.

View All

A new experience landscape

COVID-19 has disrupted the customer engagement model, but in more ways than just shifting to digital.

60_%

of patients want to use technology more for communicating with HCPs and managing their conditions.

regulatory and policy change will pose the greatest impact to margins within the next five years.

1-2_%

decline in Net Price Growth in the US over the next five years, significantly below the historical 4.3 percent growth.

84_%

Of patient said that the services they used – such as remote monitoring and payment support – were valuable during the pandemic.

Actions to modernize

The modern commercial model requires companies to commit to outcomes, design for impact, reach customers in new ways and digitally power operations. Life sciences companies can get there by:

Aligning evidence and economics to outcomes

Demonstrate outcomes through value-based models and access led transformation.

Bringing outcomes to life through experience

Designing experiences around the changing needs of patients, caregivers, and HCPs across increasingly complex care pathways.

Modernizing launch and competitive strategies

Optimizing market entry by empowering brand teams with therapeutic area expertise and executing flawlessly.

Reinventing end to end marketing

Moving away from traditional marketing tactics to positioning assets to drive growth.

Reimagining the digitized customer model

Introducing new engagement approaches to better support HCPs and patients.

Applying intelligence to commercial

Playing data offense and leaning into artificial intelligence (AI) to streamline operations.

Rewiring operations and capabilities

Strengthening core capabilities to promote and sustain commercial growth.

View All

"I believe the most overlooked permanent change will be in the relevance of what we engage our customers on more than the channels by which we engage them."

— RAY PRESSBURGER, Accenture Strategy, Commercial, Sales and Marketing, Life Sciences

What we think

Health Experience

Digital adoption: Reaction or revolution?

Our US survey of 1,755 people focuses on four themes that explore key aspects of health experiences today: Technology, Experience, Access and Trust.

Research and Development

New Science: A new economic reality for growth

As New Science grows in prominence, a new economic environment is demanding change for biopharma’s.

Patient Services

Connecting patients to the services they need

Our new research focuses on patient adoption and reveals that the patient services model needs to change.

COVID-19

Is COVID-19 altering how pharma engages with HCPs?

Precision Medicine

The experience report: Oncologist issue

COVID-19

How COVID-19 has permanently changed patient behavior

VIEW MORE ARTICLES

Blogs

VIEW MORE POSTS

Commercial

Why does patient centricity matter to pharma?

There is significant value in pharma continuing to focus on patient-centricity initiatives across the value chain. Read Why.

Commercial

Delivering an improved customer experience with AI

Across many industries, companies using AI in marketing and CX are simply outperforming those that don’t.

Life Sciences

Making the impossible possible: Galien forum 2021

Accenture's Petra Jantzer co-moderated the Galien Golden Jubilee Forum and discussed critically important lessons learned from COVID-19.

Life Sciences

A new economic reality is challenging profitability

Accenture explores how changes in personalized, complex medicines are challenging health systems’ ability to afford the care that populations require.

Life Sciences

Launching to win: Positioning assets for success

Accenture’s Katie Boyd and Frances Tulley explore the differences between beating market expectations and underperforming pharma launches.

VIEW MORE POSTS

Case studies

Life Sciences

Digitizing customer service processes

Accenture supports forces with Siemens Healthineers in digitizing its customer service processes.

Life Sciences

Gene therapy gets personal

Accenture helped a biopharma company implement a patient-centered platform to manage the delivery of a personalized gene therapy solution.

View All

Awards & recognition

Discover how our recognition and awards distinguish us as the right partner to help you define and implement the right commercial strategy for your business.

IDC MARKETPLACE

Our leaders

Ray Pressburger

Managing Director – Accenture Strategy, Commercial, Sales and Marketing, Life Sciences

Jimmy Paras

Managing Director – Consulting, Life Sciences, Commercial Services, North America

Laura Dix

Managing Director – Life Sciences, United Kingdom

Gro Blindheim

Managing Director – Life Sciences

Vinita Vasanth

Managing Director – Consulting, Life Sciences, Commercial Services, Growth Markets

Floren Robinson Pressman

Managing Director – Life Sciences Accenture Song Lead, NA

Rich Sherman

Managing Director – Intelligent Patient Services Digital Health Applications

View All

Commercial, sales & marketing services

Changing relationships with customers